Financing ·
FDA clears IND for SZN-8141, triggering $95.1M private placement closing on or about October 20, 2026
SRZNSurrozen, Inc.
Surrozen announced FDA clearance of the Investigational New Drug application for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody for diabetic macular edema. This regulatory milestone triggers the second closing of its March 2025 private placement, expected to provide approximately $95.1 million in gross proceeds on or about October 20, 2026. The company plans to dose the first patient in the DUET Phase 1b/2a study in Q4 2026, with initial data anticipated in H2 2027. Surrozen will file a Form S-3 registration statement within 30 days of closing to register resale of issued securities. The company operates in the biotechnology industry, developing therapies for retinal diseases.